分析急性生理与慢性健康评分(APACHE-Ⅱ评分)、红细胞体积分布宽度(red cell volume distribution width,RDW)及氨基末端脑利钠肽前体(NT-proBNP)与脓毒症患者预后的相关性。选取72例脓毒症患者作为研究对象,患者的入院时间为2022年1月...分析急性生理与慢性健康评分(APACHE-Ⅱ评分)、红细胞体积分布宽度(red cell volume distribution width,RDW)及氨基末端脑利钠肽前体(NT-proBNP)与脓毒症患者预后的相关性。选取72例脓毒症患者作为研究对象,患者的入院时间为2022年1月—2023年12月,按照存活与否将患者分为存活组(n=58)和病亡组(n=14),对比存活组与病亡组患者的APACHE-Ⅱ评分、RDW及NT-proBNP指标。结果显示,存活组与病亡组脓毒症患者的APACHE-Ⅱ评分、RDW及NT-proBNP差异显著,存活组脓毒症患者的APACHE-Ⅱ评分、RDW及NT-proBNP更优,差异有统计学意义(P<0.05)。BNP浓度越高,APACHE-Ⅱ评分越高,BNP浓度与APACHE-Ⅱ评分成正比。研究发现,APACHE-Ⅱ评分、RDW及NT-proB-NP与脓毒症患者的预后具有相关性。展开更多
在临床实践中,诊断和预后评估通常依赖多种实验室和评分指标。近年来,红细胞分布宽度(RDW)、中性粒细胞与淋巴细胞比值(NLR)和红细胞分布宽度与血小板计数比值(RPR)作为新兴复合实验室指标,在疾病诊断和预后评估中展现出显著价值。尤其...在临床实践中,诊断和预后评估通常依赖多种实验室和评分指标。近年来,红细胞分布宽度(RDW)、中性粒细胞与淋巴细胞比值(NLR)和红细胞分布宽度与血小板计数比值(RPR)作为新兴复合实验室指标,在疾病诊断和预后评估中展现出显著价值。尤其是在急性疾病中,这些指标因其快速获得的特性而备受关注。文章综述了RDW和RPR在脑卒中、急性心肌梗死、冠状动脉介入治疗、脓毒症及恶性肿瘤中的最新研究进展,强调其在预测疾病严重程度和预后中的潜力。研究表明,RDW和RPR作为早期获取的指标,能够有效评估上述疾病患者的病情演变和预后。其进一步研究有望推动这些指标在临床中的广泛应用。In clinical practice, diagnosis and prognosis assessment often rely on various laboratory and scoring indices. In recent years, emerging composite laboratory indices such as red blood cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), and the ratio of red blood cell distribution width to platelet count (RPR) have demonstrated significant value in disease diagnosis and prognosis evaluation. Particularly in acute diseases, these indices have gained attention due to their rapid availability. This review summarizes the latest research on RDW and RPR in conditions such as stroke, acute myocardial infarction, coronary artery interventions, sepsis, and malignancies, highlighting their potential in predicting disease severity and outcomes. Studies indicate that RDW and RPR, as early accessible markers, can effectively evaluate disease progression and prognosis in these patients. Further research is expected to promote the widespread clinical application of these indices.展开更多
文摘分析急性生理与慢性健康评分(APACHE-Ⅱ评分)、红细胞体积分布宽度(red cell volume distribution width,RDW)及氨基末端脑利钠肽前体(NT-proBNP)与脓毒症患者预后的相关性。选取72例脓毒症患者作为研究对象,患者的入院时间为2022年1月—2023年12月,按照存活与否将患者分为存活组(n=58)和病亡组(n=14),对比存活组与病亡组患者的APACHE-Ⅱ评分、RDW及NT-proBNP指标。结果显示,存活组与病亡组脓毒症患者的APACHE-Ⅱ评分、RDW及NT-proBNP差异显著,存活组脓毒症患者的APACHE-Ⅱ评分、RDW及NT-proBNP更优,差异有统计学意义(P<0.05)。BNP浓度越高,APACHE-Ⅱ评分越高,BNP浓度与APACHE-Ⅱ评分成正比。研究发现,APACHE-Ⅱ评分、RDW及NT-proB-NP与脓毒症患者的预后具有相关性。
文摘在临床实践中,诊断和预后评估通常依赖多种实验室和评分指标。近年来,红细胞分布宽度(RDW)、中性粒细胞与淋巴细胞比值(NLR)和红细胞分布宽度与血小板计数比值(RPR)作为新兴复合实验室指标,在疾病诊断和预后评估中展现出显著价值。尤其是在急性疾病中,这些指标因其快速获得的特性而备受关注。文章综述了RDW和RPR在脑卒中、急性心肌梗死、冠状动脉介入治疗、脓毒症及恶性肿瘤中的最新研究进展,强调其在预测疾病严重程度和预后中的潜力。研究表明,RDW和RPR作为早期获取的指标,能够有效评估上述疾病患者的病情演变和预后。其进一步研究有望推动这些指标在临床中的广泛应用。In clinical practice, diagnosis and prognosis assessment often rely on various laboratory and scoring indices. In recent years, emerging composite laboratory indices such as red blood cell distribution width (RDW), neutrophil-to-lymphocyte ratio (NLR), and the ratio of red blood cell distribution width to platelet count (RPR) have demonstrated significant value in disease diagnosis and prognosis evaluation. Particularly in acute diseases, these indices have gained attention due to their rapid availability. This review summarizes the latest research on RDW and RPR in conditions such as stroke, acute myocardial infarction, coronary artery interventions, sepsis, and malignancies, highlighting their potential in predicting disease severity and outcomes. Studies indicate that RDW and RPR, as early accessible markers, can effectively evaluate disease progression and prognosis in these patients. Further research is expected to promote the widespread clinical application of these indices.
